Pharmacological and Biological Targeting of FGFR1 in Cancer

Shuai Fan; Yuxin Chen; Wenyu Wang; Wanting Xu; Mei Tian; Yuetong Liu; Yutong Zhou; Dan Liu; Qin Xia; Lei Dong

doi:10.3390/cimb46110783

Pharmacological and Biological Targeting of FGFR1 in Cancer

Shuai Fan
, Yuxin Chen
, Wenyu Wang
, Wanting Xu
, Mei Tian
, Yuetong Liu
, Yutong Zhou
, Dan Liu
, Qin Xia^*
, Lei Dong^*

^*Corresponding author for this work

School of Life Science

Beijing Institute of Technology

Research output: Contribution to journal › Review article › peer-review

23 Citations (Scopus)

Abstract

FGFR1 is a key member of the fibroblast growth factor receptor family, mediating critical signaling pathways such as RAS-MAPK and PI3K-AKT. which are integral to regulating essential cellular processes, including proliferation, differentiation, and survival. Alterations in FGFR1 can lead to constitutive activation of signaling pathways that drive oncogenesis by promoting uncontrolled cell division, inhibiting apoptosis, and enhancing the metastatic potential of cancer cells. This article reviews the activation mechanisms and signaling pathways of FGFR1 and provides a detailed exposition of the types of FGFR1 aberration. Furthermore, we have compiled a comprehensive overview of current therapies targeting FGFR1 aberration in cancer, aiming to offer new perspectives for future cancer treatments by focusing on drugs that address specific FGFR1 alterations.

Original language	English
Pages (from-to)	13131-13150
Number of pages	20
Journal	Current Issues in Molecular Biology
Volume	46
Issue number	11
DOIs	https://doi.org/10.3390/cimb46110783
Publication status	Published - Nov 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

FGFR1
TKI
aberration
antibody drugs
ligand traps
targeted therapeutics

Access to Document

10.3390/cimb46110783

Cite this

@article{1ba82b27f50a4ccaac9ceffacd9af43f,

title = "Pharmacological and Biological Targeting of FGFR1 in Cancer",

abstract = "FGFR1 is a key member of the fibroblast growth factor receptor family, mediating critical signaling pathways such as RAS-MAPK and PI3K-AKT. which are integral to regulating essential cellular processes, including proliferation, differentiation, and survival. Alterations in FGFR1 can lead to constitutive activation of signaling pathways that drive oncogenesis by promoting uncontrolled cell division, inhibiting apoptosis, and enhancing the metastatic potential of cancer cells. This article reviews the activation mechanisms and signaling pathways of FGFR1 and provides a detailed exposition of the types of FGFR1 aberration. Furthermore, we have compiled a comprehensive overview of current therapies targeting FGFR1 aberration in cancer, aiming to offer new perspectives for future cancer treatments by focusing on drugs that address specific FGFR1 alterations.",

keywords = "FGFR1, TKI, aberration, antibody drugs, ligand traps, targeted therapeutics",

author = "Shuai Fan and Yuxin Chen and Wenyu Wang and Wanting Xu and Mei Tian and Yuetong Liu and Yutong Zhou and Dan Liu and Qin Xia and Lei Dong",

note = "Publisher Copyright: {\textcopyright} 2024 by the authors.",

year = "2024",

month = nov,

doi = "10.3390/cimb46110783",

language = "English",

volume = "46",

pages = "13131--13150",

journal = "Current Issues in Molecular Biology",

issn = "1467-3037",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "11",

}

TY - JOUR

T1 - Pharmacological and Biological Targeting of FGFR1 in Cancer

AU - Fan, Shuai

AU - Chen, Yuxin

AU - Wang, Wenyu

AU - Xu, Wanting

AU - Tian, Mei

AU - Liu, Yuetong

AU - Zhou, Yutong

AU - Liu, Dan

AU - Xia, Qin

AU - Dong, Lei

PY - 2024/11

Y1 - 2024/11

N2 - FGFR1 is a key member of the fibroblast growth factor receptor family, mediating critical signaling pathways such as RAS-MAPK and PI3K-AKT. which are integral to regulating essential cellular processes, including proliferation, differentiation, and survival. Alterations in FGFR1 can lead to constitutive activation of signaling pathways that drive oncogenesis by promoting uncontrolled cell division, inhibiting apoptosis, and enhancing the metastatic potential of cancer cells. This article reviews the activation mechanisms and signaling pathways of FGFR1 and provides a detailed exposition of the types of FGFR1 aberration. Furthermore, we have compiled a comprehensive overview of current therapies targeting FGFR1 aberration in cancer, aiming to offer new perspectives for future cancer treatments by focusing on drugs that address specific FGFR1 alterations.

AB - FGFR1 is a key member of the fibroblast growth factor receptor family, mediating critical signaling pathways such as RAS-MAPK and PI3K-AKT. which are integral to regulating essential cellular processes, including proliferation, differentiation, and survival. Alterations in FGFR1 can lead to constitutive activation of signaling pathways that drive oncogenesis by promoting uncontrolled cell division, inhibiting apoptosis, and enhancing the metastatic potential of cancer cells. This article reviews the activation mechanisms and signaling pathways of FGFR1 and provides a detailed exposition of the types of FGFR1 aberration. Furthermore, we have compiled a comprehensive overview of current therapies targeting FGFR1 aberration in cancer, aiming to offer new perspectives for future cancer treatments by focusing on drugs that address specific FGFR1 alterations.

KW - FGFR1

KW - TKI

KW - aberration

KW - antibody drugs

KW - ligand traps

KW - targeted therapeutics

UR - https://www.scopus.com/pages/publications/85210429977

U2 - 10.3390/cimb46110783

DO - 10.3390/cimb46110783

M3 - Review article

AN - SCOPUS:85210429977

SN - 1467-3037

VL - 46

SP - 13131

EP - 13150

JO - Current Issues in Molecular Biology

JF - Current Issues in Molecular Biology

IS - 11

ER -

Pharmacological and Biological Targeting of FGFR1 in Cancer

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this